Current Clinical Trials

This 9 month trial is recruiting treatment naive wet AMD patients to be treated with a new Regeneron drug in combination with Eylea. This combination therapy works differently than the more common Anti-VegF therapies and it is our hope that these drugs together will more effectively treat the debilitating effects of wet macular degeneration.

This trial is recruiting patients who have had 1-5 treatments with Lucentis for wet AMD to be implanted with a refillable port (filled with varying doses of Lucentis). It is our hope that this port delivery system will decrease the treatment burden of our patients and ultimately decrease how often our patients need to be seen in our clinic.

This 6 month trial is recruiting treatment naive or treatment experienced wet AMD patients to be treated with a new Anti-VegF drug, OPT-302, versus combination therapy of Lucentis and OPT-302. This new drug works similar to the more common Anti-VegF therapies but the hope is that it might work a little more effectively.

This 2 year trial is recruiting treatment naive wet AMD patients to be treated with an eye drop, Squalamine lactate, in combination with Lucentis versus Lucentis. This combination therapy works differently than the more common Anti-VegF therapies and it is our hope that these drugs together will more effectively treat the debilitating effects of wet macular degeneration.

This 2 year trial is recruiting patients who have had 1 Anti-VegF treatment for wet AMD to be treated with a new drug, Zimura, in combination with Lucentis, Avastin or Eylea. Zimura works differently than the more common Anti-VegF therapies and it is our hope that these drugs together will more effectively treat the debilitating effects of wet macular degeneration.

This 1 year trial is recruiting patients who have had 2 or more Anti-VegF treatments for wet AMD and have had incomplete resolution of intraretinal or subretinal fluid. Patients will be treated with pills, X-82, in combination with Eylea PRN. X-82 is an oral pill and it is our hope that this drug will work effectively to treat the debilitating effects of wet macular degeneration and reduce the intravitreal injection frequency for our patients.

This 2 year trial is recruiting treatment naïve wet AMD patients to be treated with a new drug, Abicipar, versus Lucentis. Abicipar works a bit differently than the more common Anti-VegF therapies and it is our hope that this drug will more effectively treat the debilitating effects of wet macular degeneration.

This 6 month trial is recruiting treatment naïve DME patients to be treated with a new drug versus Lucentis. This new drug works similar to the more common Anti-VegF therapies but the hope is that it might work a little more effectively to treat the debilitating effects of DME.

This 2 year trial is recruiting treatment naïve diabetic retinopathy patients to be treated with Eylea. Eylea is already FDA-approved for many retinal disease, however, this trial has been designed in order for Eylea to be approved for the treatment of moderate to severe non-proliferative diabetic retinopathy. The hope is that it might work to prevent the progression to proliferative diabetic retinopathy.

This 9 month study is recruiting previously treated DME patients to be treated with Dexamethasone in combination with anti VEGF versus anti VEGF alone.

This is a 2 year wet AMD trial using a new drug, Fovista, in combination with Lucentis. Fovista works differently than the more common Anti-VegF therapies and it is our hope that these drugs together will more effectively treat the debilitating effects of wet macular degeneration.

This is a 2 year wet AMD trial using a new drug, Fovista, in combination with Avastin or Eylea. Fovista works differently than the more common Anti-VegF therapies and it is our hope that these drugs together will more effectively treat the debilitating effects of wet macular degeneration.

This is a 2 year wet AMD trial using a new drug, Fovista, in combination with Lucentis, Avastin or Eylea. Fovista works differently than the more common Anti-VegF therapies and it is our hope that these drugs together will more effectively treat the debilitating effects of wet macular degeneration.

hthotech 1006 Trial
This is a 2 year wet AMD trial using a new drug, Fovista, in combination with Lucentis, Avastin or Eylea. Fovista works differently than the more common Anti-VegF therapies and it is our hope that these drugs together will more effectively treat the debilitating effects of wet macular degeneration.

This is a 1 year wet AMD trial using a new Regeneron drug in combination with Eylea. This combination therapy works differently than the more common Anti-VegF therapies and it is our hope that these drugs together will more effectively treat the debilitating effects of wet macular degeneration.

This is a 2 year DME trial consisting of 3 groups: prompt laser plus deferred anti-VEGF injection, observation plus deferred anti-VEGF injection and prompt anti-VEGF injection.

It is a 1 year trial, sponsored by NEI, assessing Avastin vs. Eylea for CRVO. This is designed as a non-inferiority trial in an effort to determine if Avastin is non-inferior to Eylea. Injections are given every 4 weeks followed by an adaptive treatment strategy where participants who were initially assigned to Eylea will be randomly reassigned to: Eylea every 4 weeks or Eylea on a treat and extend schedule. Those subjects in the Lucentis arm will then be re- randomized to: Lucentis every 4 weeks or Lucentis on a treat and extend schedule.

This is a 2 year Geographic Atrophy trial using Lampalizumab. Currently there is no approved therapy for geographic atrophy so it our hope that Lampalizumab will stop or slow the progression of geographic atrophy and its detrimental effects.

This is a 2 year wet AMD trial using 2 different doses of a new drug, ESBA1008, versus EYLEA. ESBA1008 works differently than the more common Anti-VegF therapies and it is our hope that this drug will more effectively treat the debilitating effects of wet macular degeneration.

This is a 2 year Geographic Atrophy trial using CLG561 versus CLG561 plus LFG316. Currently there is no approved therapy for geographic atrophy so it our hope that either CLG alone or the combination therapy will stop or slow the progression of geographic atrophy and its detrimental effects on patients who have that diagnosis.

This trial will be recruiting treatment naïve or previously treated DME patients to be treated with a new drug, Abicipar, versus Lucentis. Abicipar works a bit differently than the more common Anti-VegF therapies and it is our hope that this drug will more effectively treat the debilitating effects of wet macular degeneration.